<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:34:43Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:6512882" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:6512882</identifier>
        <datestamp>2019-06-10</datestamp>
        <setSpec>neurology</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Neurology</journal-id>
              <journal-id journal-id-type="iso-abbrev">Neurology</journal-id>
              <journal-id journal-id-type="hwp">neurology</journal-id>
              <journal-id journal-id-type="publisher-id">neur</journal-id>
              <journal-id journal-id-type="publisher-id">NEUROLOGY</journal-id>
              <journal-title-group>
                <journal-title>Neurology</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0028-3878</issn>
              <issn pub-type="epub">1526-632X</issn>
              <publisher>
                <publisher-name>Lippincott Williams &amp; Wilkins</publisher-name>
                <publisher-loc>Hagerstown, MD</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC6512882</article-id>
              <article-id pub-id-type="pmcid">PMC6512882</article-id>
              <article-id pub-id-type="pmc-uid">6512882</article-id>
              <article-id pub-id-type="pmid">31036580</article-id>
              <article-id pub-id-type="pmid">31036580</article-id>
              <article-id pub-id-type="publisher-id">NEUROLOGY2018923904</article-id>
              <article-id pub-id-type="doi">10.1212/WNL.0000000000006932</article-id>
              <article-categories>
                <subj-group subj-group-type="heading">
                  <subject>Null Hypothesis</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy</article-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Lochm√ºller</surname>
                    <given-names>Hanns</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>(1) German Duchenne parents project (2)IRDiRC Interdisciplinary Scientific Committee (3)German Muscular Dystrophy Network (4) Myotubular Trust Patient Registry (5) Action Duchenne Patient Registry (6) German PatientRegistries on DMD and SMA</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>(1) Journal of Neuromuscular Diseases, Editor in Chief, 2014-current (2)Journal of Neurology, Editorial Board Member, 2007-current</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>Consultancies: (1)Roche Pharmaceuticals (2)Ultragenyx Pharmaceutical Inc.(3)AMO Pharma(4)Sarepta(5) Santhera</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>(1) Ultragenyx Pharmaceutical Inc (2) AMO Pharma(3) GW Pharma</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>(1)European Commission (RD-Connect), 305444, Coordinator, 2012-2018 (2) European Commission (OPTIMISTIC), 305697, co-investigator, 2012-2016 (3)European Commission (NeurOmics), 305121, co-investigator, 2012-2017 (4)Medical Research Council (MRC), co-investigator, 2013-2018 (5)Wellcome Trust Pathfinder Award, 2016-2017</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>(1)Action Duchenne, (2) Association Francaise Contre les Myopathies (3)British Heart Foundation (4)MuscularDytrophy UK (5)National Cancer Institute (6) Spinal Muscular Atrophy Support UK (7)Wellcome Trust (8)Jennifer Trust (9)Duchenne Parent Project</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Behin</surname>
                    <given-names>Anthony</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>(1) Ultragenyx Pharmaceutical (2) Genzyme</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for travel or speaker honoraria:</title>
                        <list-item>
                          <p>(1) Ultragenyx pharmaceutical - JNLF 2017, Toulouse</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Caraco</surname>
                    <given-names>Yoseph</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>1. Frontier in Transport and Drug metabolism, Associate Editor, 4 years</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>1. I acted as a PI in the study sponsored by UltraGenyx described in the current paper. 2. EnteraBio - I am a PI in a study sponsored by EnteraBio for the evaluation of oral PTH 3. MSD - I act as a PI in a study aimed to evaluate CMV vaccine 4. Novartis - I act as a PI in a study sponsored by Novartis to study the effect of investigational product on anemia among hemodialysis patients</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lau</surname>
                    <given-names>Heather</given-names>
                  </name>
                  <degrees>MD, MS</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>1. National Tay Sachs and Allied Diseases Scientific Advisory Board 2. Adult Polyglucosan Body Disorder Foundation Scientific Advisory Board 3. Shire Advisory Board 4. Sanofi Genzyme Advisory Board</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for travel or speaker honoraria:</title>
                        <list-item>
                          <p>1. Amicus - travel/honoraria 2. Actelion travel 3. Biomarin travel/honoraria 4. Chiesi travel/honoraria 5. Indorsia travel/honoraria 6. Pfizer travel/honoraria 7. Prevail Therapeutics travel 8. Sanofi Genzyme travel/honoraria 9. Ultragenyx travel/honoraria</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>1. Sanofi Genzyme 2. Pfizer 3. Actelion 4. Ultragenyx 5. Shire 6. Prevail therapeutics 7. Amicus 8. Chiesi</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>1. Sanofi Genzyme 2. Shire 3. Amicus 4. Mallinckrodt 5. Biomarin 6. Ultragenyx 7. Pfizer 8. Protalix 9. Sangamo</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>National Tay Sachs and Allied Diseases Foundation Grant</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mirabella</surname>
                    <given-names>Massimiliano</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>Bayer Schering, Biogen, Sanofi-Genzyme, Merck Serono, Novartis, Teva</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for travel or speaker honoraria:</title>
                        <list-item>
                          <p>Almirall, Bayer Schering, Biogen, CSL Behring, Sanofi-Genzyme, Merck Serono, Novartis, Teva, Ultragenix</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other activities:</title>
                        <list-item>
                          <p>scientific advisory board membership of Bayer Schering, Biogen, Sanofi- Genzyme, Merck Serono,Novartis, Teva; consulting and/or speaking fees, research support or travel grants from Almirall, Bayer Schering, Biogen, CSL Behring, Sanofi-Genzyme, Merck Serono, Novartis, Teva, Ultragenix; principal investigator in clinical trials for Biogen, Merck Serono, Novartis, Roche, Sanofi Genzyme, Teva, Ultragenix.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tournev</surname>
                    <given-names>Ivailo</given-names>
                  </name>
                  <degrees>MD, DSc</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Tarnopolsky</surname>
                    <given-names>Mark</given-names>
                  </name>
                  <degrees>PhD, MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>Genzyme - North American Registry Board.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for travel or speaker honoraria:</title>
                        <list-item>
                          <p>1) Sanofi/Genzyme - 1-3 talks/year on mitochondrial and neuromuscular disease (2012-present).</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>Editorial board of Mitochondrion.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>1. US and Canadian patent pending - The use of IL-15 in metabolic disorders.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>CEO and CSO of Exerkine Corporation - We are working on protein delivery systems and nutritional approaches for neurological genetic disorders, obesity and aging. I receive no remuneration but have shares in the company.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>Genzyme Canada - Pompe study 2012-2014 - no personal remuneration - research costs only.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NSERC, Principle Investigator 2012-2017 - Multi-systemic benefits of exercise. CIHR, Principle Investigator 2012-current - Exosomes as mediators of the multi-systemic benefits of exercise.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>Barth Syndrome - Scientific Advisory Board (2015-present). Stock/Stock Options, Medical Equipment &amp; Materials: 1. Exerkine - stockholder.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Pogoryelova</surname>
                    <given-names>Oksana</given-names>
                  </name>
                  <degrees>PhD, MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Woods</surname>
                    <given-names>Catherine</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical Inc., Senior Manager Medical Writing, May 2017-current (1.5 years).</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical Inc., 1.5 years</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Lai</surname>
                    <given-names>Alexander</given-names>
                  </name>
                  <degrees>PhD, MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical Inc., Senior Medical Director, 2 years approximately Stock/Stock Options, Medical Equipment &amp; Materials: Ultragenyx Pharmaceutical Inc., 2 years approximately</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Shah</surname>
                    <given-names>Jinay</given-names>
                  </name>
                  <degrees>RPh, MS</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical Inc; Associate Director, Global Clinical Development; September 2015 to present</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Koutsoukos</surname>
                    <given-names>Tony</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical inc VP Biostatistics 5 years</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>I am an Ultragenyx Pharmaceutical salary employee.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Skrinar</surname>
                    <given-names>Alison</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Employee of Ultragenyx Pharmaceutical Inc from March 2012 - present</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>Stock holder of Ultragenyx Pharmaceutical Inc., the sponsor of the study</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mansbach</surname>
                    <given-names>Hank</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx; VP, Global Clinical Development; 3.5 years</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>Ultragenyx</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kakkis</surname>
                    <given-names>Emil</given-names>
                  </name>
                  <degrees>PhD, MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for Travel or Speaker Honoraria:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>Extended release sialic acid drug technology</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical, Chief Executive Officer, 8 years</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other Activities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>Ultragenyx Pharmaceutical, stock ownership as employee and as founder</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Mozaffar</surname>
                    <given-names>Tahseen</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <author-comment content-type="disclosure">
                    <p>
                      <list list-type="order">
                        <title>Scientific Advisory Boards:</title>
                        <list-item>
                          <p>On Medical and Scientific Advisory Board for the Myositis Association, Amicus, Biomarin, Genzyme, Idera Pharmaceuticals, and Ultragenyx</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Gifts:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Funding for travel or speaker honoraria:</title>
                        <list-item>
                          <p>Received travel reimbursement for advisory board meeting for 1) Genzyme Corporation; 2) Biomarin; and 3) Amicus</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Editorial Boards:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Patents:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Publishing Royalties:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Employment, Commercial Entity:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Consultancies:</title>
                        <list-item>
                          <p>1) Commercial or non-profit entity: Amicus, 2) Commercial or non-profit entity: Biomarin, 3) Commercial or non-profit entity: Genzyme, 4) Commercial or non-profit entity: Sarepta and 5) Commercial or non-profit entity: Ultragenyx 6) Commercial or non-profit entity: OptionCare 7) Commercial or non-profit entity: Spark Therapeutics</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Speakers' Bureaus:</title>
                        <list-item>
                          <p>1) Commercial or non-profit entity: Genzyme Corporation 2) Commercial or non-profit entity: Grifols</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Other activities:</title>
                        <list-item>
                          <p>received financial support from NuFACTOR, Inc. during the course of this study.</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Clinical Procedures or Imaging Studies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Commercial Entities:</title>
                        <list-item>
                          <p>1) Commercial or non-profit entity: Alnylam 2) Commercial or non-profit entity: Alexion 3) Commercial or non-profit entity: Amicus 4) Commercial or non-profit entity: Biomarin 5) Commercial or non-profit entity: CSL Behring 6) Commercial or non-profit entity: Genzyme 7) Commercial or non-profit entity: Ionis 8) Commercial or non-profit entity: GSK 9) Commercial or non-profit entity: Novartis 10) Commercial or non-profit entity: Ultragenyx 11) Commercial or non-profit entity: Grifols 12) Commercial or non-profit entity: Octapharma</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Government Entities:</title>
                        <list-item>
                          <p>NIH Funding (co-investigator on R01NS049203) 2009-2014</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Academic Entities:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Research Support, Foundations and Societies:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options/Board of Directors Compensation:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>License Fee Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Royalty Payments, Technology or Inventions:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Research Sponsor:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Stock/Stock Options, Medical Equipment &amp; Materials:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                    <p>
                      <list list-type="order">
                        <title>Legal Proceedings:</title>
                        <list-item>
                          <p>NONE</p>
                        </list-item>
                      </list>
                    </p>
                  </author-comment>
                </contrib>
                <aff>From the Institute of Genetic Medicine (H.L., O.P.), Newcastle University, Newcastle upon Tyne, UK; Children's Hospital of Eastern Ontario Research Institute (H.L.), University of Ottawa; Division of Neurology, Department of Medicine (H.L.), The Ottawa Hospital, Canada; APHP (A.B.), Centre de R√©f√©rence de Pathologie Neuromusculaire, Institut de Myologie, Groupe Hospitalier Piti√©-Salp√™tri√®re, Paris, France; Hadassah Clinical Research Center (Y.C.), Hadassah-Hebrew University Medical Center, Jerusalem, Israel; Department of Neurology, Division of Neurogenetics (H.L.), NYU School of Medicine, New York, NY; Fondazione Policlinico Universitario A. Gemelli IRCCS (M.M.), Catholic University, Rome, Italy; Expert Center of Genetic Neurologic and Metabolic Disorders (I.T.), University Hospital Aleksandrovska, Sofia; Department of Neurology (I.T.), Medical University Sofia; Department of Cognitive Science and Psychology (I.T.), New Bulgarian University, Sofia, Bulgaria; Department of Pediatrics, Neuromuscular and Neurometabolic Clinic (M.T.), McMaster University Medical Center, Hamilton, Canada; Ultragenyx Pharmaceutical Inc. (C.W., A.L., J.S., T.K., A.S., H.M., E.K.), Novato, CA; and University of California Irvine (T.M.), Orange. H.L. is currently affiliated with the Department of Neuropediatrics and Muscle Disorders, Medical Center, University of Freiburg, Faculty of Medicine, Germany.</aff>
              </contrib-group>
              <author-notes>
                <corresp><bold>Correspondence</bold> Dr. Lochm√ºller <email>hanns.lochmuller@gmail.com</email></corresp>
                <fn fn-type="financial-disclosure">
                  <p>Go to <ext-link xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000006932" ext-link-type="uri">Neurology.org/N</ext-link> for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article.</p>
                </fn>
                <fn fn-type="other">
                  <p>The Article Processing Charge was funded by Ultragenyx Pharmaceutical Inc.</p>
                </fn>
              </author-notes>
              <pub-date pub-type="ppub">
                <day>30</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>30</day>
                <month>4</month>
                <year>2019</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>.-->
              <volume>92</volume>
              <issue>18</issue>
              <fpage>e2109</fpage>
              <lpage>e2117</lpage>
              <history>
                <date date-type="received">
                  <day>25</day>
                  <month>7</month>
                  <year>2018</year>
                </date>
                <date date-type="accepted">
                  <day>20</day>
                  <month>11</month>
                  <year>2018</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright ¬© 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</copyright-statement>
                <copyright-year>2019</copyright-year>
                <copyright-holder>American Academy of Neurology</copyright-holder>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND)</ext-link>, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.</license-p>
                </license>
              </permissions>
              <self-uri xlink:title="pdf" xlink:href="NEUROLOGY2018923904.pdf"/>
              <abstract>
                <sec>
                  <title>Objective</title>
                  <p>To investigate the efficacy and safety of aceneuramic acid extended-release (Ace-ER), a treatment intended to replace deficient sialic acid, in patients with GNE myopathy.</p>
                </sec>
                <sec>
                  <title>Methods</title>
                  <p>UX001-CL301 was a phase 3, double-blind, placebo-controlled, randomized, international study evaluating the efficacy and safety of Ace-ER in patients with GNE myopathy. Participants who could walk ‚â•200 meters in a 6-minute walk test at screening were randomized 1:1, and stratified by sex, to receive Ace-ER 6 g/d or placebo for 48 weeks and assessed every 8 weeks. The primary endpoint was change in muscle strength over 48 weeks measured by upper extremity composite (UEC) score. Key secondary endpoints included change in lower extremity composite (LEC) score, knee extensor strength, and GNE myopathy‚ÄìFunctional Activity Scale (GNEM-FAS) mobility domain score. Safety assessments included adverse events (AEs), vital signs, and clinical laboratory results.</p>
                </sec>
                <sec>
                  <title>Results</title>
                  <p>Eighty-nine patients were randomized (Ace-ER n = 45; placebo n = 44). Change from baseline to week 48 for UEC score between treatments did not differ (least square mean [LSM] Ace-ER ‚àí2.25 kg vs placebo ‚àí2.99 kg; LSM difference confidence interval [CI] 0.74 [‚àí1.61 to 3.09]; <italic toggle="yes">p</italic> = 0.5387). At week 48, there was no significant difference between treatments for the change in key secondary endpoints: LEC LSM difference (CI) ‚àí1.49 (‚àí5.83 to 2.86); knee extension strength ‚àí0.40 (‚àí2.38 to 1.58); and GNEM-FAS mobility domain score ‚àí0.72 (‚àí2.01 to 0.57). Gastrointestinal events were the most common AEs.</p>
                </sec>
                <sec>
                  <title>Conclusions</title>
                  <p>Ace-ER was not superior to placebo in improving muscle strength and function in patients with GNE myopathy.</p>
                </sec>
                <sec>
                  <title>Classification of evidence</title>
                  <p>This study provides Class I evidence that for patients with GNE myopathy, Ace-ER does not improve muscle strength compared to placebo.</p>
                </sec>
              </abstract>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>OPEN-ACCESS</meta-name>
                  <meta-value>TRUE</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>STATUS</meta-name>
                  <meta-value>ONLINE-ONLY</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
          </front>
          <body>
            <p>GNE myopathy (hereditary inclusion body myopathy) is a rare, severely debilitating, adult-onset myopathy caused by mutation in <italic toggle="yes">GNE</italic>, a gene encoding 2 sequential enzymes critical to the biosynthesis of sialic acid (SA).<sup><xref rid="R1" ref-type="bibr">1</xref></sup> GNE myopathy typically presents with distal muscle weakness, proceeding proximally with relative sparing of the quadriceps, compromising arm and leg muscle function. Disease progression is gradual and variable, with loss of ambulation ranging from 10 to 20 years after onset.<sup><xref rid="R2" ref-type="bibr">2</xref>,<xref rid="R3" ref-type="bibr">3</xref></sup> Data from a GNE myopathy disease monitoring program (GNEM-DMP; NCT01784679) suggest that muscle strength can decline by roughly 10% in &lt;2 years.<sup><xref rid="R4" ref-type="bibr">4</xref></sup></p>
            <p>Currently, there is no approved therapy and few clinical trials investigating treatments for GNE myopathy. Consistent with the hypothesis that disease pathology arises from decreased SA in skeletal muscle, preclinical models have shown efficacy by supplementing SA.<sup><xref rid="R5" ref-type="bibr">5</xref><xref rid="R6" ref-type="bibr">‚Äì</xref><xref rid="R9" ref-type="bibr">9</xref></sup> Oral SA supplementation in a GNE myopathy mouse model (GNE D176V) increased serum SA in tissue and reduced pathology and loss of function in muscle.<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Since oral SA can be rapidly cleared from the body, an extended-release formulation of SA, aceneuramic acid extended-release (Ace-ER), was developed to promote muscle uptake from continuous, elevated serum SA.<sup><xref rid="R10" ref-type="bibr">10</xref></sup></p>
            <p>In a phase 2, dose-finding, placebo-crossover study, Ace-ER 6 g/d demonstrated stabilization in upper extremity (UE) strength in 47 patients with GNE myopathy over 48 weeks. Here, we report results of a phase 3, placebo-controlled study investigating the efficacy and safety of Ace-ER in 89 participants with GNE myopathy, the largest clinical trial to date in GNE myopathy.</p>
            <sec sec-type="methods" id="s1">
              <title>Methods</title>
              <sec id="s1-1">
                <title>Study population</title>
                <p>Patients with GNE myopathy were enrolled at 13 sites from 7 countries: Bulgaria, Canada, France, Israel, Italy, United Kingdom, and United States. Some patients were recruited through the GNEM-DMP. Eligible participants met the following key inclusion criteria: 18‚Äì55 years of age; documented diagnosis due to previously demonstrated mutations in the <italic toggle="yes">GNE</italic> gene (genotyping was not conducted as part of the study); able to provide 2 dynamometry force values in elbow flexors with ‚â§15% variability in the dominant arm at screening; and able to walk ‚â•200 meters in the 6-minute walk test (6MWT) at screening, which indicates that patients are more likely to have sufficient muscle tissue to observe a treatment effect from a substrate replacement therapy. Patients were not eligible if they met the following key exclusion criteria: use of N-acetyl-<sc>d</sc>-mannosamine (ManNAc), SA, SA-related metabolites, IV immunoglobulin, or other substance that can be metabolized to produce SA in the body within 60 days of screening; &gt;30 days treatment with SA (extended or immediate release) in prior clinical trial in the last year; hypersensitivity to SA or its excipients; and serum transaminase &gt;3 times the upper limit of normal for age/sex, or serum creatinine &gt;2 times upper limit at screening.</p>
              </sec>
              <sec id="s1-2">
                <title>Study design and endpoints</title>
                <p>UX001-CL301 (NCT02377921) was a phase 3, double-blind, placebo-controlled, multicenter, randomized, international study providing Class 1 evidence that Ace-ER does not improve muscle strength compared to placebo in patients with GNE myopathy (<xref rid="F1" ref-type="fig">figure 1</xref>). Eligible patients were randomized 1:1, stratified by sex, to receive 6 g/d of Ace-ER or matching placebo orally 3 times a day for 48 weeks. Dose selection was based on the previous phase 2 trial and long-term extension, which demonstrated that 6 g/d of Ace-ER was efficacious while 3 g/d was not; 12 g/d was not more efficacious than 6 g/d, had a substantial pill burden, and was associated with a higher incidence of gastrointestinal adverse events.<sup><xref rid="R10" ref-type="bibr">10</xref><xref rid="R11" ref-type="bibr">‚Äì</xref><xref rid="R12" ref-type="bibr">12</xref></sup> In addition, the placebo tablets in this phase 3 study were the same as those used in the phase 2 study.</p>
                <fig position="float" id="F1">
                  <label>Figure 1</label>
                  <caption>
                    <title>UX001-CL301 study design</title>
                    <p>6MWT = 6-minute walk test; Ace-ER = aceneuramic acid extended-release; GNEM = GNE myopathy.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904FF1" position="float"/>
                </fig>
                <p>The endpoints evaluated in UX001-CL301 were determined by analysis of phase 2 data (UX001-CL201; NCT01517880) assessing outcome measures capable of characterizing the pattern and extent of muscle weakness associated with GNE myopathy and functional limitations resulting from this weakness.<sup><xref rid="R13" ref-type="bibr">13</xref></sup> All efficacy assessments were conducted on site at screening or baseline and every 8 weeks following baseline.</p>
                <p>The primary endpoint was change from baseline in muscle strength based on the UE composite (UEC) score after 48 weeks of treatment and was used to compare treatment groups. Because coordinated engagement of multiple muscles is necessary for gross motor function and a composite muscle score can provide more clinically valuable information in a disease with variable decline across muscle groups, regulatory authorities agreed that the UEC was an appropriate primary efficacy endpoint. A hand-held dynamometer (HHD) was used to assess muscle strength. The UEC was calculated as the sum of the mean of bilateral HHD scores from grip, shoulder abductors, elbow flexors, and elbow extensors. Physical therapists at each site underwent extensive training to improve intrarater and inter-rater reliability on all HHD assessments.</p>
                <p>For key secondary endpoints, the following change from baseline to week 48 was evaluated for both treatment groups: lower extremity (LE) muscle strength composite (LEC) score, muscle strength in knee extensors, and physical functioning as measured using the GNE myopathy‚ÄìFunctional Activity Scale (GNEM-FAS) mobility domain score.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup> The GNEM-FAS is a validated instrument with qualitative and quantitative measures designed to assess functional impairment in GNE myopathy including mobility, UE function, and self-care; higher GNEM-FAS scores indicate a lower level of impairment. LEC was calculated as the sum of the following muscle groups using HHD: hip abductors and adductors, hip flexors and extensors, and knee flexors. Knee extensor muscle strength was also measured by HHD. The following additional secondary endpoints were also evaluated for both treatment groups at week 48: physical functioning as measured using the GNEM-FAS UE domain score<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>; UE function as measured by a timed weighted arm lift test<sup><xref rid="R15" ref-type="bibr">15</xref></sup>; LE function as measured by a timed Sit-to-Stand Test<sup><xref rid="R15" ref-type="bibr">15</xref>,<xref rid="R16" ref-type="bibr">16</xref></sup>; LE function as measured by distance walked in the 6MWT<sup><xref rid="R17" ref-type="bibr">17</xref></sup>; and the quality of life questionnaire for neuromuscular disease.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> Blood samples were collected at baseline and prior to drug administration every 8 weeks thereafter to assess change in free serum SA using liquid chromatography atmospheric pressure ionization mass spectrometry (response range 0.0400‚Äì20.0 Œºg/mL) performed by Intertek Pharmaceutical Services (San Diego, CA).</p>
                <p>Safety assessments included the incidence, frequency, and severity of adverse events (AEs) as well as changes in vital signs and clinical laboratory tests. Changes in platelet level were also examined since a recent study reported on a potential link between mutations in GNE and thrombocytopenia.<sup><xref rid="R19" ref-type="bibr">19</xref></sup> Safety assessments were collected at the same time points as efficacy assessments, as well as over the phone at treatment week 4 and approximately 28 days after the participant's last dose of study drug.</p>
                <p>For additional details, the full protocol is provided in the supplementary materials.</p>
              </sec>
              <sec id="s1-3">
                <title>Statistical analysis</title>
                <p>The primary efficacy analysis set was based on participants with both baseline and postbaseline data. The 2 treatment groups were compared using the generalized estimating equation model with baseline, sex, and region (United States vs non‚ÄìUnited States) as covariates. Data are summarized as mean, least squares mean (LSM), range, standard error, confidence interval (95% CI), and the number or percentage of participants. This phase 3 study aimed to enroll at least 80 participants to provide 90% power to detect a difference of about 5 kg in the change from baseline in UEC score between treatment groups, assuming an SD of 6 kg and a 2-sided Œ± of 0.05. This calculation was based on the phase 2 study showing that patients able to walk more than 200 meters in the 6MWT at baseline experienced a greater effect of Ace-ER in the UEC; in addition, a change of 5 kg in UEC would be approximately a 9% decline in UE muscle strength in this phase 3 study population, and therefore suggested to be clinically meaningful.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> Safety analysis was based on all randomized patients who received at least 1 dose of study drug.</p>
                <p>A regression analysis was performed to determine whether clinical outcomes were influenced by variables such as study site, baseline status, age, and time since diagnosis. Due to the heterogeneity of the population and lack of a full sample set, a genotype‚Äìphenotype analysis was not performed.</p>
              </sec>
              <sec id="s1-4">
                <title>Standard protocol approvals, registrations, and patient consents</title>
                <p>UX001-CL301 was designed, conducted, recorded, and reported in accordance with ethical principles, consistent with ICH GCP guidelines, and in accordance with applicable local, federal, and regulatory agency regulations. Institutional review boards at each site approved the protocol prior to site initiation. The study is registered with <ext-link xlink:href="http://ClinicalTrials.gov" ext-link-type="uri">ClinicalTrials.gov</ext-link> (NCT02377921) and the EU Register (2014-005432-33). The principal investigator had access to the data and all authors have reviewed key findings and have access to study documents.</p>
              </sec>
              <sec sec-type="data-availability" id="s1-5">
                <title>Data availability</title>
                <p>Individual de-identified participant data will be available for 12 months from the time of publication upon request to researchers providing a methodologically sound proposal for analysis for research that contributes to the field of GNE myopathy. Proposals should be directed to <email>clinicaldatarequest@ultragenyx.com</email>. To gain access, data requestors will need to sign a data access and use agreement. Data will be shared via secured portal.</p>
              </sec>
            </sec>
            <sec sec-type="results" id="s2">
              <title>Results</title>
              <sec id="s2-1">
                <title>Baseline demographics and characteristics</title>
                <p>A total of 89 participants with GNE myopathy based on previous documentation of a pathogenic variant of the GNE/MNK enzyme were screened and randomized (figure e-1, <ext-link xlink:href="https://doi.org/10.5061/dryad.h52h5t7" ext-link-type="uri">doi.org/10.5061/dryad.h52h5t7</ext-link>). The safety analysis population included 44 participants treated with placebo and 45 participants treated with Ace-ER. Two participants, 1 from each treatment group, discontinued due to noncompliance; 1 of these 2 participants had no postbaseline assessments and was excluded from the placebo group for the primary efficacy data set, which included 43 participants treated with placebo and 45 participants treated with Ace-ER.</p>
                <p>Baseline demographics and characteristics were generally well balanced between treatment groups (<xref rid="T1" ref-type="table">table 1</xref>). Both groups had similarly low free serum SA.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Notably, despite the range in time from diagnosis to enrollment (0‚Äì20 years), both treatment groups showed substantial impairments in muscle strength at baseline compared with population norms, with the LE muscles more severely impaired than UE muscles<sup><xref rid="R21" ref-type="bibr">21</xref><xref rid="R22" ref-type="bibr">‚Äì</xref><xref rid="R24" ref-type="bibr">24</xref></sup> (<xref rid="F2" ref-type="fig">figure 2</xref>). The baseline percentage of normal predicted UE muscle strength, including grip, shoulder abductors, elbow flexors, and elbow extensors, ranged from 51% to 65% for placebo and 50% to 60% for the Ace-ER group. Baseline percentage of normal predicted LE muscle strength, including hip abductors, hip adductors, hip flexors, hip extensors, and knee flexors, ranged from 15% to 64% for the placebo group and 13% to 64% for the Ace-ER group; the percentage of normal muscle strength for hip flexors was the lowest compared to other muscles for both treatment groups. Knee extensor strength was similar for both treatment groups as well (percentage of normal predicted: placebo 62%, Ace-ER 58%) and demonstrated the relative sparing of the quadriceps characteristic of GNE myopathy.</p>
                <table-wrap position="float" id="T1">
                  <label>Table 1</label>
                  <caption>
                    <p>Baseline characteristics</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904TT1" position="float"/>
                </table-wrap>
                <fig position="float" id="F2">
                  <label>Figure 2</label>
                  <caption>
                    <title>Percentage predicted muscle strength at baseline</title>
                    <p>Ace-ER = aceneuramic acid extended-release.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904FF2" position="float"/>
                </fig>
              </sec>
              <sec id="s2-2">
                <title>Efficacy findings</title>
                <p>Consistent with the phase 2 findings, serum SA increased from baseline (0.16 Œºg/mL) to week 48 (0.30 Œºg/mL) with Ace-ER treatment, but not with placebo treatment (0.16 Œºg/mL at both baseline and week 48; <xref rid="F3" ref-type="fig">figure 3</xref>). The peak mean increase in serum SA, 2.3 times the mean baseline value, was observed at week 16. The change from baseline to week 48 in SA was significantly different between treatment groups (Ace-ER LSM change [95% CI] 0.14 [0.10 to 0.18]; placebo 0.00 [‚àí0.01 to 0.02]; <italic toggle="yes">p</italic> &lt; 0.0001).</p>
                <fig position="float" id="F3">
                  <label>Figure 3</label>
                  <caption>
                    <title>Free serum sialic acid</title>
                    <p>Data are expressed as mean ¬± standard error. Gray lines indicate placebo; blue lines indicate aceneuramic acid extended-release (Ace-ER).</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904FF3" position="float"/>
                </fig>
                <p>UX001-CL301 did not meet the primary endpoint, as there was no significant difference between treatment groups in the change from baseline to week 48 for UEC score (LSM placebo ‚àí2.99 kg vs Ace-ER ‚àí2.25 kg; LSM difference 0.74, <italic toggle="yes">p</italic> = 0.54) (<xref rid="F4" ref-type="fig">figure 4</xref>). The baseline UEC score was 56 kg for both placebo and Ace-ER. Week 48 UEC score was 53 kg for placebo and 54 kg for Ace-ER. The 2.99 kg decline in the placebo group was below the 5 kg target difference in the prevention of decline for which the study was designed. Similar results were obtained when analyzing the UEC as change in percentage predicted norm (LSM placebo ‚àí2.85% vs Ace-ER ‚àí2.05%; LSM difference 0.80, <italic toggle="yes">p</italic> = 0.55). The change from baseline for each individual muscle group within the UEC did not differ between treatment groups (table e-1, <ext-link xlink:href="https://doi.org/10.5061/dryad.h52h5t7" ext-link-type="uri">doi.org/10.5061/dryad.h52h5t7</ext-link>).</p>
                <fig position="float" id="F4">
                  <label>Figure 4</label>
                  <caption>
                    <title>Change from baseline in primary and key secondary efficacy assessments</title>
                    <p>(A‚ÄìD) Data are expressed as mean change from baseline ¬± standard error. Gray lines indicate placebo; blue lines indicate aceneuramic acid extended-release (Ace-ER). GNEM-FAS = GNE myopathy‚ÄìFunctional Activity Scale; LEC = lower extremity composite; UEC = upper extremity composite.</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904FF4" position="float"/>
                </fig>
                <p>After 48 weeks of treatment, there was also no significant difference between treatment groups for the 3 prespecified key secondary endpoints (<xref rid="F2" ref-type="fig">figure 2</xref>). The baseline mean LEC score was 55 kg for placebo and 54 kg for Ace-ER. There was no significant difference between treatment groups in week 48 mean LEC score, with 53 kg for placebo and 51 kg for Ace-ER (LSM difference [95% CI] ‚àí1.49 [‚àí5.83 to 2.86]; <italic toggle="yes">p</italic> = 0.50). The mean baseline knee extensor strength was 27 kg for both placebo and Ace-ER. Mean knee extensor strength at week 48 was similar between groups, with minimal to no increase (placebo 27 kg, Ace-ER 26 kg; LSM difference [95% CI] ‚àí0.40 [‚àí2.38 to 1.58]; <italic toggle="yes">p</italic> = 0.69). The mean GNEM-FAS mobility score at baseline was 26 for both placebo and Ace-ER. There was no difference between treatment groups in mean GNEM-FAS mobility score at week 48, with 25 for placebo and 24 for Ace-ER (LSM difference [95% CI] ‚àí0.72 [‚àí2.01 to 0.57]; <italic toggle="yes">p</italic> = 0.27). Finally, there was no significant difference in the change from baseline between treatments in any of the additional endpoints (<xref rid="T2" ref-type="table">table 2</xref>). Study site, baseline status, age, and time since diagnosis did not affect clinical outcome findings.</p>
                <table-wrap position="float" id="T2">
                  <label>Table 2</label>
                  <caption>
                    <p>Change from baseline to week 48 in additional efficacy endpoints</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904TT2" position="float"/>
                </table-wrap>
              </sec>
              <sec id="s2-3">
                <title>Safety</title>
                <p>Overall, Ace-ER was well-tolerated and the most common AEs were mild to moderate gastrointestinal events (<xref rid="T3" ref-type="table">table 3</xref>). There were no deaths or grade 4 AEs. There were 2 serious AEs (SAEs) in the Ace-ER group (grade 3 acute myocardial infarction and grade 2 acute gastritis) and 1 SAE in the placebo group (abortion); all SAEs resolved and only the acute gastritis SAE was considered possibly treatment-related.</p>
                <table-wrap position="float" id="T3">
                  <label>Table 3</label>
                  <caption>
                    <p>Safety</p>
                  </caption>
                  <graphic xlink:href="NEUROLOGY2018923904TT3" position="float"/>
                </table-wrap>
                <p>There were no noteworthy differences in vital signs and laboratory findings for either treatment group. Platelet counts at baseline were similar across treatment groups. At week 48, platelet count for 1 participant in Ace-ER shifted from normal to high but was not considered clinically significant. No noteworthy shift in platelet counts was observed in the placebo group.</p>
              </sec>
            </sec>
            <sec sec-type="discussion" id="s3">
              <title>Discussion</title>
              <p>Very few clinical studies have been conducted for distal myopathies, and there have been no phase 3 clinical trials investigating treatments for any distal myopathy, including GNE myopathy.<sup><xref rid="R25" ref-type="bibr">25</xref></sup> The rarity of distal myopathies results in a lack of confirmed diagnosis, patient cohorts, suitable and testable outcome measures, clinical trial expertise, and understanding disease course; this absence renders clinical research more challenging as compared to more common neurologic and neuromuscular diseases.</p>
              <p>GNE myopathy is characterized by progressive loss of muscle strength due to impairment in the production of SA, which plays a role in muscle cellular health.<sup><xref rid="R26" ref-type="bibr">26</xref><xref rid="R27" ref-type="bibr">‚Äì</xref><xref rid="R29" ref-type="bibr">29</xref></sup> The scientific rationale for the Ace-ER program was to replace the underlying deficiency in SA and thereby slow the progressive loss of muscle strength and function. UX001-CL301 investigated the efficacy and safety of Ace-ER compared to placebo in the first phase 3 study in GNE myopathy. The phase 3 study was unable to confirm the benefit observed in the prior phase 2 study. Compared to placebo, Ace-ER did not demonstrate a treatment benefit on primary or secondary measures of muscle strength and function; there was no significant treatment effect for Ace-ER compared to placebo in any exploratory endpoints. Overall, Ace-ER exhibited an acceptable safety profile.</p>
              <p>Both the phase 2 study and this phase 3 study demonstrate that Ace-ER significantly increased serum SA.<sup><xref rid="R10" ref-type="bibr">10</xref></sup> However, efficacy findings from the phase 3 study differed from findings in the phase 2 study. In the phase 2 study with 47 patients with GNE myopathy, Ace-ER 6 g/d resulted in maintenance of muscle strength in UEC score at 6 g/d compared with placebo at week 24<sup><xref rid="R10" ref-type="bibr">10</xref></sup> and sustained responses at week 48. Variation in the population and size of these 2 studies may account for the differences in outcomes. The phase 3 study included 3 times the number of participants receiving Ace-ER 6/day for a full 48 weeks than the phase 2 study dose-finding placebo-crossover study. The phase 3 population was also more heterogeneous, with patients recruited from many more countries and with greater genetic heterogeneity (data not shown) than in the phase 2 (Israel and United States only). Further, participants in the phase 3 study were less impaired at baseline than in the phase 2 study. A greater percentage of participants reported using a walking device at baseline in the phase 2 study than the phase 3 study (33% vs 18%). At baseline, the GNEM-FAS total score in the phase 2 study was 69; participants in the Ace-ER and placebo group in the phase 3 study scored 79 and 81, respectively.</p>
              <p>In addition to comparing the phase 2 and phase 3 study populations at baseline, we can contrast the magnitude of change in clinical outcomes through 24 weeks of treatment. Given that the expected treatment benefit was slowing of disease progression relative to placebo, the phase 3 study outcome was particularly sensitive to the extent of strength decline in placebo group. The decline in UEC score at week 24 in placebo groups was as follows: phase 2 study mean change (SD) ‚àí1.95 (3.10) kg; 5% decline vs phase 3 study change ‚àí1.06 (5.43) kg; 2%.<sup><xref rid="R4" ref-type="bibr">4</xref>,<xref rid="R10" ref-type="bibr">10</xref></sup> Only after 48 weeks did the placebo group in the phase 3 study observe a 6% decline (‚àí3.28 [5.83] kg); the placebo group did not continue beyond 24 weeks in the phase 2 study. Consistent with observations from this phase 3 study, recent findings from the GNEM-DMP, representing a larger natural history population of patients with GNE myopathy, also suggest a slower decline in UE muscle strength than observed in the phase 2 study; the mean decline in 74 patients was ‚àí2.02 kg and ‚àí3.31 kg after 12 and 24 months of monitoring without treatment, respectively.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> For treatment strategies that aim to slow disease progression, it is possible that a treatment duration longer than 48 weeks may be necessary to establish a treatment benefit.</p>
              <p>Further biological hypotheses to be investigated include the lack of sufficient tissue levels (SA in muscle), compensatory downregulation of SA transport into the target tissue, altered cellular processing, or alternative, noncanonical functions of the GNE gene or protein itself. In the latter scenario, SA supplementation alone, however effective, would not restore muscle cell function.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> It is also possible that the underlying pathophysiology of the disease may extend beyond a deficiency in SA.</p>
              <p>In spite of findings from this phase 3 study showing that Ace-ER was not superior to placebo, development of therapeutics that target the mechanism of disease of GNE myopathy, or the SA biosynthetic pathway, may still prove beneficial. SA does not penetrate muscles well. However, different formulations of extended-release SA may be able to further penetrate muscle cells, replenish the deficient pool of SA, and slow the rate of muscle decline. Oral treatment with ManNAc, a precursor in the SA biosynthetic pathway, prevented muscle weakness in a murine model of GNE myopathy and is now being studied in an open-label phase 2 study in patients with GNE myopathy (NCT02346461).<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Gene therapy is also being explored to treat GNE myopathy.<sup><xref rid="R1" ref-type="bibr">1</xref>,<xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup></p>
              <p>UX001-CL301 was the largest clinical trial in patients with GNE myopathy and provided novel perspective on conducting trials in patients with distal myopathies. Due to the rarity of GNE myopathy, the phase 3 study included 13 clinical trial sites across 7 different countries. This geographic reach raises disease awareness and sets the stage for future studies in GNE myopathy. Findings from this phase 3 study also provide insight into the heterogeneity of GNE myopathy, especially with the rate of progression. In addition, in collaboration with TREAT-NMD, a network of clinicians and scientists performing neuromuscular research, data from this study alongside natural history data from the GNEM-DMP are available for interested parties in an effort to develop treatments for GNE myopathy. Understanding the differences between patients with GNE myopathy will continue to help develop outcome measures sensitive and specific enough for early detection of the therapy efficacy. One of the most promising highlights from the clinical trials investigating the efficacy and safety of Ace-ER was the development of the GNEM-FAS, another validated tool that will set the stage for future clinical studies in the GNE myopathy population.<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup></p>
              <p>We investigated the efficacy and safety of an extended-release formulation of SA, Ace-ER, in the largest clinical trial in GNE myopathy, UX001-CL301. Overall, Ace-ER was well-tolerated, but did not demonstrate superiority over placebo in measures of muscle strength. The heterogeneity of patients participating in this study and the rate of disease progression provided valuable insight into how future studies can assess efficacy in clinical trials with distal myopathies.</p>
            </sec>
          </body>
          <back>
            <ack>
              <title>Acknowledgment</title>
              <p>The authors thank the patients, their parents/caregivers, and health care professionals who participated in this study, including Dean Miller; Ruth Wake; Dionne Moat; Robert Muni Lofra; Teresinha Evangelista, MD; Nikoletta Nikolenko, MD; Namita Goyal, MD; Sonia Nayyar, MD; Caroline Peyronnard, MD; Tim Lai, MD; Monica Lavian, DO; Brian Minton, BS; Patrick Tierney, RPT; Denise Davis, RPT; Cathy Chou, RPT; Nick Higgins; and Ed Connor, MD.</p>
            </ack>
            <fn-group>
              <fn fn-type="supplementary-material">
                <p>Class of Evidence: <ext-link xlink:href="http://NPub.org/coe" ext-link-type="uri">NPub.org/coe</ext-link></p>
              </fn>
            </fn-group>
            <sec sec-type="contributions">
              <title>Author contributions</title>
              <p content-type="contributions">H.L., T.K., A.S., and E.K. contributed to the study design. H.L., A.B., Y.C., H.L., M.M., I.T., M.T., O.P., A.L., J.S., T.K., A.S., H.M., and E.K. contributed to the acquisition of data, analysis, and interpretation of study. All authors contributed to the development of this manuscript, and reviewed and approved the final version for submission.</p>
            </sec>
            <sec sec-type="funding">
              <title>Study funding</title>
              <p content-type="funding">Supported by Ultragenyx Pharmaceutical Inc. The sponsor, Ultragenyx Pharmaceutical Inc., and investigators were responsible for collecting, analyzing, and interpreting data. The authors vouch for the completeness and accuracy of the data. This article was written with input from all authors and medical writing support provided by the sponsors. The lead author had access to the data and all authors decided to submit this manuscript. The project described was supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH, through grant UL1 TR001414. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. The Article Processing Charge was funded by Ultragenyx Pharmaceutical Inc.</p>
            </sec>
            <sec sec-type="coi-statement">
              <title>Disclosure</title>
              <p>H. Lochm√ºller has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. Financial support to Newcastle University and the Newcastle NHS Trust for research projects and clinical trials was provided by AMO Pharma, Biogen, GW Pharma, Pfizer, PTC Therapeutics, Roche, and Ultragenyx. A. Behin has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. Y. Caraco has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. His institution, Hadassah University Hospital, has received financial support for research projects and clinical trials by EnteraBio, Bioblast, Boehringer Ingelheim, Sanofi Aventis, Synektik, LeukoDx, Novartis, BiolineRx, and Ultragenyx. H. Lau has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. She has also conducted clinical research for Amicus, Biomarin, Genzyme/Sanofi, Pfizer, Mallinckrodt, Shire, and Ultragenyx. She has consulted for Actelion, Biomarin, Chiesi, Genzyme/Sanofi, Pfizer, Prevail Therapeutics, and Shire. She has served on an advisory board for Genzyme/Sanofi, Shire, and Ultragenyx. M. Mirabella has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. I. Tournev has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. M. Tarnopolsky has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. He is the president and CEO of Exerkine Corporation. O. Pogoryelova has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. A. Lai is employed by and holds stock options with Ultragenyx Pharmaceutical Inc. J. Shah is employed by and holds stock options with Ultragenyx Pharmaceutical Inc. T. Koutsoukos is employed and holds stock options with Ultragenyx Pharmaceutical Inc. A. Skrinar is employed and holds stock options with Ultragenyx Pharmaceutical Inc. H. Mansbach is employed and holds stock options with Ultragenyx Pharmaceutical Inc. E. Kakkis is employed and holds stock options with Ultragenyx Pharmaceutical Inc. T. Mozaffar has served as a clinical trial investigator for Ultragenyx Pharmaceutical Inc. Go to <ext-link xlink:href="http://n.neurology.org/lookup/doi/10.1212/WNL.0000000000006932" ext-link-type="uri">Neurology.org/N</ext-link> for full disclosures.</p>
            </sec>
            <glossary>
              <title>Glossary</title>
              <def-list>
                <def-item>
                  <term id="G1">6MWT</term>
                  <def>
                    <p>6-minute walk test</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G2">Ace-ER</term>
                  <def>
                    <p>aceneuramic acid extended-release</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G3">AE</term>
                  <def>
                    <p>adverse event</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G4">CI</term>
                  <def>
                    <p>confidence interval</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G5">GNEM-DMP</term>
                  <def>
                    <p>GNE myopathy disease monitoring program</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G6">GNEM-FAS</term>
                  <def>
                    <p>GNE myopathy‚ÄìFunctional Activity Scale</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G7">HHD</term>
                  <def>
                    <p>hand-held dynamometer</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G8">LE</term>
                  <def>
                    <p>lower extremity</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G9">LEC</term>
                  <def>
                    <p>lower extremity composite</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G10">LSM</term>
                  <def>
                    <p>least squares mean</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G11">ManNAc</term>
                  <def>
                    <p>N-acetyl-d-mannosamine</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G12">SA</term>
                  <def>
                    <p>sialic acid</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G13">SAE</term>
                  <def>
                    <p>serious adverse event</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G14">UE</term>
                  <def>
                    <p>upper extremity</p>
                  </def>
                </def-item>
                <def-item>
                  <term id="G15">UEC</term>
                  <def>
                    <p>upper extremity composite</p>
                  </def>
                </def-item>
              </def-list>
            </glossary>
            <ref-list>
              <title>References</title>
              <ref id="R1">
                <label>1.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nishino</surname><given-names>I</given-names></string-name>, <string-name><surname>Carrillo-Carrasco</surname><given-names>N</given-names></string-name>, <string-name><surname>Argov</surname><given-names>Z</given-names></string-name></person-group>. <article-title>GNE myopathy: current update and future therapy</article-title>. <source>J Neurol Neurosurg Psychiatry</source><year>2015</year>;<volume>86</volume>:<fpage>385</fpage>‚Äì<lpage>392</lpage>.<pub-id pub-id-type="pmid">25002140</pub-id></mixed-citation>
              </ref>
              <ref id="R2">
                <label>2.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nonaka</surname><given-names>I</given-names></string-name>, <string-name><surname>Noguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Nishino</surname><given-names>I</given-names></string-name></person-group>. <article-title>Distal myopathy with rimmed vacuoles and hereditary inclusion body myopathy</article-title>. <source>Curr Neurol Neurosci Rep</source><year>2005</year>;<volume>5</volume>:<fpage>61</fpage>‚Äì<lpage>65</lpage>.<pub-id pub-id-type="pmid">15676110</pub-id></mixed-citation>
              </ref>
              <ref id="R3">
                <label>3.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pogoryelova</surname><given-names>O</given-names></string-name>, <string-name><surname>Cammish</surname><given-names>P</given-names></string-name>, <string-name><surname>Mansbach</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Phenotypic stratification and genotype-phenotype correlation in a heterogeneous, international cohort of GNE myopathy patients: first report from the GNE myopathy Disease Monitoring Program, registry portion</article-title>. <source>Neuromuscul Disord</source><year>2017</year>;<volume>28</volume>:<fpage>158</fpage>‚Äì<lpage>168</lpage>.<pub-id pub-id-type="pmid">29305133</pub-id></mixed-citation>
              </ref>
              <ref id="R4">
                <label>4.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Behin</surname><given-names>A</given-names></string-name>, <string-name><surname>Mozaffar</surname><given-names>T</given-names></string-name>, <string-name><surname>Tarnopolsky</surname><given-names>M</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>GNE-myopathy (HIBM): upper and lower extremity muscle strength declines over time in a prospective study</article-title>. <source>Neuromuscul Disord</source><year>2017</year>;<volume>27</volume>(<issue>suppl 2</issue>):<fpage>S51</fpage>‚Äì<lpage>S270</lpage>.</mixed-citation>
              </ref>
              <ref id="R5">
                <label>5.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Varki</surname><given-names>NM</given-names></string-name>, <string-name><surname>Varki</surname><given-names>A</given-names></string-name></person-group>. <article-title>Diversity in cell surface sialic acid presentations: implications for biology and disease</article-title>. <source>Lab Invest</source><year>2007</year>;<volume>87</volume>:<fpage>851</fpage>‚Äì<lpage>857</lpage>.<pub-id pub-id-type="pmid">17632542</pub-id></mixed-citation>
              </ref>
              <ref id="R6">
                <label>6.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chan</surname><given-names>YM</given-names></string-name>, <string-name><surname>Lee</surname><given-names>P</given-names></string-name>, <string-name><surname>Jungles</surname><given-names>S</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Substantial deficiency of free sialic acid in muscles of patients with GNE myopathy and in a mouse model</article-title>. <source>PLoS One</source><year>2017</year>;<volume>12</volume>:<fpage>e0173261</fpage>.<pub-id pub-id-type="pmid">28267778</pub-id></mixed-citation>
              </ref>
              <ref id="R7">
                <label>7.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malicdan</surname><given-names>MC</given-names></string-name>, <string-name><surname>Noguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Hayashi</surname><given-names>YK</given-names></string-name>, <string-name><surname>Nonaka</surname><given-names>I</given-names></string-name>, <string-name><surname>Nishino</surname><given-names>I</given-names></string-name></person-group>. <article-title>Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model</article-title>. <source>Nat Med</source><year>2009</year>;<volume>15</volume>:<fpage>690</fpage>‚Äì<lpage>695</lpage>.<pub-id pub-id-type="pmid">19448634</pub-id></mixed-citation>
              </ref>
              <ref id="R8">
                <label>8.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yonekawa</surname><given-names>T</given-names></string-name>, <string-name><surname>Malicdan</surname><given-names>MC</given-names></string-name>, <string-name><surname>Cho</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Sialyllactose ameliorates myopathic phenotypes in symptomatic GNE myopathy model mice</article-title>. <source>Brain</source><year>2014</year>;<volume>137</volume>:<fpage>2670</fpage>‚Äì<lpage>2679</lpage>.<pub-id pub-id-type="pmid">25062695</pub-id></mixed-citation>
              </ref>
              <ref id="R9">
                <label>9.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Malicdan</surname><given-names>MC</given-names></string-name>, <string-name><surname>Noguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Tokutomi</surname><given-names>T</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Peracetylated N-acetylmannosamine, a synthetic sugar molecule, efficiently rescues muscle phenotype and biochemical defects in mouse model of sialic acid-deficient myopathy</article-title>. <source>J Biol Chem</source><year>2012</year>;<volume>287</volume>:<fpage>2689</fpage>‚Äì<lpage>2705</lpage>.<pub-id pub-id-type="pmid">22157763</pub-id></mixed-citation>
              </ref>
              <ref id="R10">
                <label>10.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argov</surname><given-names>Z</given-names></string-name>, <string-name><surname>Caraco</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lau</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Aceneuramic acid extended release administration maintains upper limb muscle strength in a 48-week study of subjects with GNE myopathy: results from a phase 2, randomized, controlled study</article-title>. <source>J Neuromuscul Dis</source><year>2016</year>;<volume>3</volume>:<fpage>49</fpage>‚Äì<lpage>66</lpage>.<pub-id pub-id-type="pmid">27854209</pub-id></mixed-citation>
              </ref>
              <ref id="R11">
                <label>11.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argov</surname><given-names>Z</given-names></string-name>, <string-name><surname>Caraco</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lau</surname><given-names>H</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Oral sialic acid extended release (SA-ER) stabilizes upper extremity muscle strength in human GNE myopathy: a phase 2 study</article-title>. <source>Neurology</source><year>2014</year>;<volume>83</volume>:<fpage>e35</fpage>.</mixed-citation>
              </ref>
              <ref id="R12">
                <label>12.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lau</surname><given-names>H</given-names></string-name>, <string-name><surname>Argov</surname><given-names>Z</given-names></string-name>, <string-name><surname>Caraco</surname><given-names>Y</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>GO 27: randomized controlled phase 2 study of GNE myopathy subjects treated with placebo, 6 g or 3 g doses of extended-release sialic acid (SA-ER) and an extension study at a higher 12 g dose of combination extended and immediate release sialic acid (SA)</article-title>. <source>Neuromuscul Disord</source><year>2014</year>;<volume>24</volume>:<fpage>923</fpage>.</mixed-citation>
              </ref>
              <ref id="R13">
                <label>13.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Argov</surname><given-names>Z</given-names></string-name>, <string-name><surname>Bronstein</surname><given-names>F</given-names></string-name>, <string-name><surname>Esposito</surname><given-names>A</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Characterization of strength and function in ambulatory adults with GNE myopathy</article-title>. <source>J Clin Neuromuscul Dis</source><year>2017</year>;<volume>19</volume>:<fpage>19</fpage>‚Äì<lpage>26</lpage>.<pub-id pub-id-type="pmid">28827485</pub-id></mixed-citation>
              </ref>
              <ref id="R14">
                <label>14.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mayhew</surname><given-names>J</given-names></string-name>, <string-name><surname>Bonner</surname><given-names>N</given-names></string-name>, <string-name><surname>Arbuckle</surname><given-names>R</given-names></string-name>, <string-name><surname>Turnbull</surname><given-names>A</given-names></string-name>, <string-name><surname>Bowden</surname><given-names>A</given-names></string-name>, <string-name><surname>Skrinar</surname><given-names>A</given-names></string-name></person-group>. <article-title>Development and preliminary evidence of the psychometric properties of the GNE myopathy functional activity scale</article-title>. <source>J Comp effectiveness Res</source><year>2017</year>;<volume>7</volume>:<fpage>381</fpage>‚Äì<lpage>395</lpage>.</mixed-citation>
              </ref>
              <ref id="R15">
                <label>15.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Agarwal</surname><given-names>S</given-names></string-name>, <string-name><surname>Kiely</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Two simple, reliable and valid tests of proximal muscle function, and their application to the management of idiopathic inflammatory myositis</article-title>. <source>Rheumatology</source><year>2006</year>;<volume>45</volume>:<fpage>874</fpage>‚Äì<lpage>879</lpage>.<pub-id pub-id-type="pmid">16449366</pub-id></mixed-citation>
              </ref>
              <ref id="R16">
                <label>16.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ozalevli</surname><given-names>S</given-names></string-name>, <string-name><surname>Ozden</surname><given-names>A</given-names></string-name>, <string-name><surname>Itil</surname><given-names>O</given-names></string-name>, <string-name><surname>Akkoclu</surname><given-names>A</given-names></string-name></person-group>. <article-title>Comparison of the Sit-to-Stand Test with 6 min walk test in patients with chronic obstructive pulmonary disease</article-title>. <source>Respir Med</source><year>2007</year>;<volume>101</volume>:<fpage>286</fpage>‚Äì<lpage>293</lpage>.<pub-id pub-id-type="pmid">16806873</pub-id></mixed-citation>
              </ref>
              <ref id="R17">
                <label>17.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chetta</surname><given-names>A</given-names></string-name>, <string-name><surname>Zanini</surname><given-names>A</given-names></string-name>, <string-name><surname>Pisi</surname><given-names>G</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reference values for the 6-min walk test in healthy subjects 20‚Äì50 years old</article-title>. <source>Respir Med</source><year>2006</year>;<volume>100</volume>:<fpage>1573</fpage>‚Äì<lpage>1578</lpage>.<pub-id pub-id-type="pmid">16466676</pub-id></mixed-citation>
              </ref>
              <ref id="R18">
                <label>18.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vincent</surname><given-names>KA</given-names></string-name>, <string-name><surname>Carr</surname><given-names>AJ</given-names></string-name>, <string-name><surname>Walburn</surname><given-names>J</given-names></string-name>, <string-name><surname>Scott</surname><given-names>DL</given-names></string-name>, <string-name><surname>Rose</surname><given-names>MR</given-names></string-name></person-group>. <article-title>Construction and validation of a quality of life questionnaire for neuromuscular disease (INQoL)</article-title>. <source>Neurology</source><year>2007</year>;<volume>68</volume>:<fpage>1051</fpage>‚Äì<lpage>1057</lpage>.<pub-id pub-id-type="pmid">17389311</pub-id></mixed-citation>
              </ref>
              <ref id="R19">
                <label>19.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Izumi</surname><given-names>R</given-names></string-name>, <string-name><surname>Niihori</surname><given-names>T</given-names></string-name>, <string-name><surname>Suzuki</surname><given-names>N</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>GNE myopathy associated with congenital thrombocytopenia: a report of two siblings</article-title>. <source>Neuromuscul Disord</source><year>2014</year>;<volume>24</volume>:<fpage>1068</fpage>‚Äì<lpage>1072</lpage>.<pub-id pub-id-type="pmid">25257349</pub-id></mixed-citation>
              </ref>
              <ref id="R20">
                <label>20.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sillanaukee</surname><given-names>P</given-names></string-name>, <string-name><surname>Ponnio</surname><given-names>M</given-names></string-name>, <string-name><surname>Jaaskelainen</surname><given-names>IP</given-names></string-name></person-group>. <article-title>Occurrence of sialic acids in healthy humans and different disorders</article-title>. <source>Eur J Clin Invest</source><year>1999</year>;<volume>29</volume>:<fpage>413</fpage>‚Äì<lpage>425</lpage>.<pub-id pub-id-type="pmid">10354198</pub-id></mixed-citation>
              </ref>
              <ref id="R21">
                <label>21.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bohannon</surname><given-names>RW</given-names></string-name></person-group>. <article-title>Reference values for extremity muscle strength obtained by hand-held dynamometry from adults aged 20 to 79 years</article-title>. <source>Arch Phys Med Rehabil</source><year>1997</year>;<volume>78</volume>:<fpage>26</fpage>‚Äì<lpage>32</lpage>.<pub-id pub-id-type="pmid">9014953</pub-id></mixed-citation>
              </ref>
              <ref id="R22">
                <label>22.</label>
                <mixed-citation publication-type="journal"><collab>NIMS</collab>. <article-title>Muscular weakness assessment: use of normal isometric strength data: The National Isometric Muscle Strength (NIMS) Database Consortium</article-title>. <source>Arch Phys Med Rehabil</source><year>1996</year>;<volume>77</volume>:<fpage>1251</fpage>‚Äì<lpage>1255</lpage>.<pub-id pub-id-type="pmid">8976307</pub-id></mixed-citation>
              </ref>
              <ref id="R23">
                <label>23.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mathiowetz</surname><given-names>V</given-names></string-name>, <string-name><surname>Kashman</surname><given-names>N</given-names></string-name>, <string-name><surname>Volland</surname><given-names>G</given-names></string-name>, <string-name><surname>Weber</surname><given-names>K</given-names></string-name>, <string-name><surname>Dowe</surname><given-names>M</given-names></string-name>, <string-name><surname>Rogers</surname><given-names>S</given-names></string-name></person-group>. <article-title>Grip and pinch strength: normative data for adults</article-title>. <source>Arch Phys Med Rehabil</source><year>1985</year>;<volume>66</volume>:<fpage>69</fpage>‚Äì<lpage>74</lpage>.<pub-id pub-id-type="pmid">3970660</pub-id></mixed-citation>
              </ref>
              <ref id="R24">
                <label>24.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bohannon</surname><given-names>RW</given-names></string-name>, <string-name><surname>Peolsson</surname><given-names>A</given-names></string-name>, <string-name><surname>Massy-Westropp</surname><given-names>N</given-names></string-name>, <string-name><surname>Desrosiers</surname><given-names>J</given-names></string-name>, <string-name><surname>Bear-Lehman</surname><given-names>J</given-names></string-name></person-group>. <article-title>Reference values for adult grip strength measured with a Jamar dynamometer: a descriptive meta-analysis</article-title>. <source>Physiotherapy</source><year>2006</year>;<volume>92</volume>:<fpage>11</fpage>‚Äì<lpage>15</lpage>.</mixed-citation>
              </ref>
              <ref id="R25">
                <label>25.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Palmio</surname><given-names>J</given-names></string-name>, <string-name><surname>Udd</surname><given-names>B</given-names></string-name></person-group>. <article-title>Myofibrillar and distal myopathies</article-title>. <source>Rev Neurol</source><year>2016</year>;<volume>172</volume>:<fpage>587</fpage>‚Äì<lpage>593</lpage>.<pub-id pub-id-type="pmid">27638134</pub-id></mixed-citation>
              </ref>
              <ref id="R26">
                <label>26.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Noguchi</surname><given-names>S</given-names></string-name>, <string-name><surname>Keira</surname><given-names>Y</given-names></string-name>, <string-name><surname>Murayama</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Reduction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles</article-title>. <source>J Biol Chem</source><year>2004</year>;<volume>279</volume>:<fpage>11402</fpage>‚Äì<lpage>11407</lpage>.<pub-id pub-id-type="pmid">14707127</pub-id></mixed-citation>
              </ref>
              <ref id="R27">
                <label>27.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Saito</surname><given-names>F</given-names></string-name>, <string-name><surname>Tomimitsu</surname><given-names>H</given-names></string-name>, <string-name><surname>Arai</surname><given-names>K</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>A Japanese patient with distal myopathy with rimmed vacuoles: missense mutations in the epimerase domain of the UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) gene accompanied by hyposialylation of skeletal muscle glycoproteins</article-title>. <source>Neuromuscul Disord</source><year>2004</year>;<volume>14</volume>:<fpage>158</fpage>‚Äì<lpage>161</lpage>.<pub-id pub-id-type="pmid">14733963</pub-id></mixed-citation>
              </ref>
              <ref id="R28">
                <label>28.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Andrew</surname><given-names>CG</given-names></string-name>, <string-name><surname>Appel</surname><given-names>SH</given-names></string-name></person-group>. <article-title>Macromolecular characterization of muscle membranes I: proteins and sialic acid of normal and denervated muscle</article-title>. <source>J Biol Chem</source><year>1973</year>;<volume>248</volume>:<fpage>5156</fpage>‚Äì<lpage>5163</lpage>.<pub-id pub-id-type="pmid">4268694</pub-id></mixed-citation>
              </ref>
              <ref id="R29">
                <label>29.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ervasti</surname><given-names>JM</given-names></string-name>, <string-name><surname>Burwell</surname><given-names>AL</given-names></string-name>, <string-name><surname>Geissler</surname><given-names>AL</given-names></string-name></person-group>. <article-title>Tissue-specific heterogeneity in alpha-dystroglycan sialoglycosylation: skeletal muscle alpha-dystroglycan is a latent receptor for <italic toggle="yes">Vicia villosa</italic> agglutinin b4 masked by sialic acid modification</article-title>. <source>J Biol Chem</source><year>1997</year>;<volume>272</volume>:<fpage>22315</fpage>‚Äì<lpage>22321</lpage>.<pub-id pub-id-type="pmid">9268382</pub-id></mixed-citation>
              </ref>
              <ref id="R30">
                <label>30.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Harazi</surname><given-names>A</given-names></string-name>, <string-name><surname>Becker-Cohen</surname><given-names>M</given-names></string-name>, <string-name><surname>Zer</surname><given-names>H</given-names></string-name>, <string-name><surname>Moshel</surname><given-names>O</given-names></string-name>, <string-name><surname>Hinderlich</surname><given-names>S</given-names></string-name>, <string-name><surname>Mitrani-Rosenbaum</surname><given-names>S</given-names></string-name></person-group>. <article-title>The interaction of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase (GNE) and alpha-actinin 2 is altered in GNE myopathy M743T mutant</article-title>. <source>Mol Neurobiol</source><year>2017</year>;<volume>54</volume>:<fpage>2928</fpage>‚Äì<lpage>2938</lpage>.<pub-id pub-id-type="pmid">27023225</pub-id></mixed-citation>
              </ref>
              <ref id="R31">
                <label>31.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Xu</surname><given-names>X</given-names></string-name>, <string-name><surname>Wang</surname><given-names>AQ</given-names></string-name>, <string-name><surname>Latham</surname><given-names>LL</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Safety, pharmacokinetics and sialic acid production after oral administration of N-acetylmannosamine (ManNAc) to subjects with GNE myopathy</article-title>. <source>Mol Genet Metab</source><year>2017</year>;<volume>122</volume>:<fpage>126</fpage>‚Äì<lpage>134</lpage>.<pub-id pub-id-type="pmid">28641925</pub-id></mixed-citation>
              </ref>
              <ref id="R32">
                <label>32.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nemunaitis</surname><given-names>G</given-names></string-name>, <string-name><surname>Jay</surname><given-names>CM</given-names></string-name>, <string-name><surname>Maples</surname><given-names>PB</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex</article-title>. <source>Hum Gene Ther</source><year>2011</year>;<volume>22</volume>:<fpage>1331</fpage>‚Äì<lpage>1341</lpage>.<pub-id pub-id-type="pmid">21517694</pub-id></mixed-citation>
              </ref>
              <ref id="R33">
                <label>33.</label>
                <mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nemunaitis</surname><given-names>G</given-names></string-name>, <string-name><surname>Maples</surname><given-names>PB</given-names></string-name>, <string-name><surname>Jay</surname><given-names>C</given-names></string-name>, <etal>et al</etal></person-group>. <article-title>Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy</article-title>. <source>J Gene Med</source><year>2010</year>;<volume>12</volume>:<fpage>403</fpage>‚Äì<lpage>412</lpage>.<pub-id pub-id-type="pmid">20440751</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
